ClinConnect ClinConnect Logo
Search / Trial NCT03191708

Trial Information

Current as of August 27, 2025

Completed

Keywords

Fractional Flow Reserve Quantitative Coronary Angiography Coronary Artery Disease Angina Pectoris Quantitative Flow Ratio

ClinConnect Summary

Patients at high risk of having one or more coronary stenosis are evaluated routinely by invasive coronary angiography. Lesions are often quantified by QCA, but fractional flow reserve is increasingly used to assess functional significance of identified stenosis. FFR is assessed during CAG by advancing a wire with a pressure transducer towards the stenosis and measure the ratio in pressure between the two sides of the stenosis during medical induced maximum blood flow (hyperemia).

The solid evidence for FFR evaluation of coronary stenosis and the relative simplicity in performing the measu...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • General Criteria:
  • Stable and unstable angina pectoris or secondary evaluation of stenosis after acute MI
  • Age \> 18 years
  • Able to provide signed informed consent
  • Angiographic inclusion criteria:
  • At least one stenosis with diameter stenosis of 30%-90% by visual estimate
  • Reference vessel size \> 2 mm in stenotic segment by visual estimate
  • Exclusion Criteria:
  • General Criteria:
  • Ineligible for diagnostic intervention or FFR examination
  • Myocardial infarction within 72 hours
  • Severe heart failure (NYHA≥III)
  • S-creatinine\>150µmol/L or GFR\<45 ml/kg/1.73m2
  • Allergy to contrast agent or adenosine
  • Factors that might substantially impact the angiographic image quality, e.g, frequent atrial premature beat or atrial fibrillation
  • Angiographic exclusion criteria:
  • The interrogated stenosis is caused by myocardial bridge
  • Ostial lesions less than 3 mm to the aorta
  • Side branches of the bifurcation lesions with Median Classification of 111 or 101
  • Poor angiographic image quality precluding contour detection
  • Severe overlap of stenotic segments
  • Severe tortuosity of target vessel

About China National Center For Cardiovascular Diseases

The China National Center for Cardiovascular Diseases (NCCD) is a leading research and clinical trial sponsor dedicated to advancing cardiovascular health in China and globally. As a prominent institution, NCCD focuses on innovative research, clinical management, and education in cardiovascular medicine. The center plays a crucial role in conducting rigorous clinical trials aimed at developing new therapies and improving patient outcomes for cardiovascular diseases. Through collaboration with national and international partners, NCCD is committed to enhancing the understanding of cardiovascular conditions and translating research findings into practical applications for improved healthcare.

Locations

Beijing, , China

Beijing, , China

Guangzhou, , China

Beijing, Beijing, China

Shanghai, , China

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials